trial

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

NCTId NCT00087542
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 60
Sponsored by ACADIA Pharmaceuticals Inc.
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
60
Study type
Interventional
Allocation
Randomized
Model
—
Masking
Double
Start
2004-03
Primary completion
—
Eligibility
ALL · 0 Years

Interventions & indications

Drugs
Pimavanserin

Sponsors

ACADIA Pharmaceuticals Inc.Lead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
60
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
Pimavanserin
drug
lead_sponsor
ACADIA Pharmaceuticals Inc.
company
indication
Hallucinations
indication
Hallucinations
indication
Psychotic Disorders
indication